Zacks Investment Research
19 Jun 2026, 12:41 UTC · 1h ago
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
19 Jun 2026, 12:41 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AtriCure reiterated its long-term goal of reaching $1 billion in revenue by 2030 during the Goldman Sachs Global Healthcare Conference. — Long-term revenue targets provide a growth roadmap that generally supports higher valuation multiples.
+0.40AtriCure reported accelerated enrollment in its BoxX-NoAF clinical trial, which may substantially broaden its addressable market. — Faster clinical progress and market expansion potential act as positive catalysts for medical device stock prices.
+0.30AtriCure is expected to post quarterly earnings of $0.03 per share, representing a year-over-year increase of 250%. — Strong projected year-over-year earnings growth is typically a positive driver for short-term price action.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
The consensus EPS estimate for AtriCure has remained unchanged over the last 30 days. — The lack of upward earnings revisions may limit the sustainability of the recent price rally.
-0.10Which stocks this story touches
Shares rallied 6.2% due to renewed investor optimism and positive long-term growth prospects discussed at a conference.
Shares finished the last trading session 4.1% higher and have returned 10.2% over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
37m ago
